The health sector posted modest gains on Tuesday, with a handful of drug developers such as Eli Lilly, Biogen and Merck outperforming the broader index.
Hims and Hers Health inked a deal to acquire European health platform Zava. Hims stock fell.
Roche said a drug combination, Tecentriq combined with lurbinectedin, shows survival benefits for patients with extensive-stage small-cell lung cancer. The Swiss pharmaceutical company said that late-stage trials showed the combination led to a 46% reduction in the risk of the disease progressing or death, and 27% reduction in the risk of death. Roche shares fell in the European session.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
June 03, 2025 17:11 ET (21:11 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。